We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow

By LabMedica International staff writers
Posted on 20 Feb 2026

Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. More...

Yet consistent, repeatable bacillary assessment across programs can be difficult, and variability in slide reading affects workflow efficiency. A new system has launched that digitizes and standardizes smear workflows with artificial intelligence to automate acid‑fast bacilli detection and objective bacillary grading.

OptraSCAN has introduced BactoSiA, an artificial intelligence-assisted tuberculosis treatment monitoring and follow‑up solution built to support sputum smear microscopy. The system is designed to deliver slide‑to‑report results in minutes and generate standardized bacillary load grades (Scanty, 1+, 2+, 3+) aligned with internationally recognized tuberculosis reporting guidelines. It targets consistent interpretation to support downstream decision‑making within existing laboratory operations.

BactoSiA combines high‑resolution brightfield whole‑slide imaging with AI-based algorithms to automatically detect and quantify acid‑fast bacilli (AFB) on Ziehl–Neelsen-stained sputum samples. Powered by OptraSCAN’s patented OS‑SiA technology, the platform performs scanning, indexing, and AI‑driven analysis simultaneously. During acquisition, likely positive regions are flagged to support slide triage, confirmed positives are graded automatically using standardized criteria, and images and reports are managed within the IMAGEPath software ecosystem.

The system is optimized for public health laboratories, mid‑ and high‑volume tuberculosis laboratories, mobile units, nongovernmental organizations, and telepathology networks where repeat testing and treatment monitoring are routine. It is designed to reduce reader variability, improve throughput, and maintain operational efficiency across diverse and decentralized settings with digital reporting and minimal infrastructure and training requirements. The approach addresses the need for speed, standardization, and scalability in smear microscopy workflows.

OptraSCAN introduced BactoSiA at WHX Labs World Health Expo in Dubai 2026, where the company conducted live, hands-on demonstrations at its booth. As part of the event’s Clinical Microbiology Track, Devika Gholap, Chief Product Officer at OptraSCAN, delivered a technology and innovation spotlight presentation titled “Implementation Science Considerations for Digitally Enabled Tuberculosis Microscopy”. The session examined practical considerations for scaling digital and AI-enabled TB microscopy, drawing on real-world laboratory and screening program experience.

“Tuberculosis care cascade depends on how well different tools work together within real‑world health systems,” said Devika Gholap, Chief Product Officer at OptraSCAN. “By bringing automation and standardized bacillary grading to one of the most widely used TB tests in the world, BactoSiA helps laboratories reduce reader variability, improve throughput, and deliver more consistent results, without adding operational complexity. This approach supports real‑world implementation at scale.”

Related Links
OptraSCAN


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Urine Analyzer
respons® UDS100
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.